1. Treatment of Organ Confined Prostate Cancer with Third Generation Cryosurgery: Preliminary Multicenter Experience
- Author
-
Roland Ugarte, Amnon Zisman, Horst Zincke, Joe Y. Lee, Stacy J. Childs, Ken-ryu Han, Lance A. Mynderse, Susan D. Sweat, Yan Moore, Allan J. Pantuck, Barry Shuman, James Lugg, Neal D. Shore, Hyung L. Kim, Ralph Miller, Jeffrey Cohen, Torrence M. Wilson, Maury A. Jayson, Danielo G. Freitas, Arie S. Belldegrun, and Carlos A. Cuevas
- Subjects
medicine.medical_specialty ,Prostatectomy ,Urinary retention ,business.industry ,Urology ,medicine.medical_treatment ,Percutaneous Cryosurgery ,Brachytherapy ,medicine.disease ,Cryosurgery ,Surgery ,Prostate-specific antigen ,Prostate cancer ,medicine.anatomical_structure ,Prostate ,medicine ,medicine.symptom ,business - Abstract
Purpose: Cryosurgical ablation of the prostate is 1 approach to the treatment of localized prostate cancer. Third generation cryosurgery uses gas driven probes that allow for a decrease in probe diameter to 17 gauge (1.5 mm). The safety, morbidity and preliminary prostate specific antigen (PSA) results of 122 cases are reported.Materials and Methods: A total of 106 patients have undergone percutaneous cryosurgery using a brachytherapy template with at least 12 months of PSA followup. Immediate and delayed morbidities were evaluated. PSA results at 3 and 12 months were recorded, and failure was defined as the inability to reach a nadir of 0.4 ng/ml or less.Results: Complications in patients undergoing primary cryosurgery included tissue sloughing (5%), incontinence (pads, 3%), urge incontinence/no pads (5%), transient urinary retention (3.3%) and rectal discomfort (2.6%). There were no cases of fistulas or infections. Postoperative impotence was 87% in previously potent patients. For patients who u...
- Published
- 2003
- Full Text
- View/download PDF